Dual-antiplatelet Therapy Strategies for Elective PCI in a Real-world Setting

Inclusion Criteria:

• Adult men and women aged at least 18 years
• Scheduled for diagnostic CAG due to suspected obstructive coronary artery disease

Exclusion Criteria:

• Presence of contra-indications for the use of clopidogrel (hypersensitivity or knownallergy to clopidogrel, severe liver insufficiency, resent or active pathologicalbleeding, patients known to be poor CYP2C19 metabolizers, patients usingpharmacological CYP2C19 inhibitors and inducers)
• Patients using clopidogrel for other reasons than the scheduled diagnostic CAG (e.g.due to previous stroke)
• Patients using P2Y12 inhibitors other than clopidogrel (e.g. prasugrel, ticagrelor,cangrelor)
• Patients using VKA (e.g. acenocoumarol, fenprocoumon)
• Patients using DOAC/NOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban)
• Inability to give informed consent (e.g., language barrier)
• Patients who have a documented mentioning of previous denial to any trialparticipation in the electronic patient dossier